Encompass Health (NYSE:EHC) Now Covered by Analysts at SVB Leerink

SVB Leerink began coverage on shares of Encompass Health (NYSE:EHC) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage set an “outperform” rating and a $100.00 price target on the stock. SVB Leerink’s price target points to a potential upside of 16.41% from the company’s current price.

EHC has been the subject of a number of other research reports. Royal Bank of Canada increased their target price on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 22nd. Stephens reiterated an “overweight” rating and set a $94.00 target price on shares of Encompass Health in a research report on Wednesday, June 5th. Barclays increased their target price on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Raymond James restated a “strong-buy” rating and issued a $95.00 price objective (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Finally, Mizuho raised their price objective on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health has an average rating of “Buy” and an average price target of $94.75.

Encompass Health Price Performance

EHC opened at $85.90 on Wednesday. The firm has a market cap of $8.65 billion, a P/E ratio of 23.22, a PEG ratio of 1.31 and a beta of 0.89. The firm has a 50-day moving average of $85.23 and a 200 day moving average of $78.60. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. Encompass Health has a fifty-two week low of $57.55 and a fifty-two week high of $87.94.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.19. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.27 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The firm’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.88 earnings per share. On average, research analysts expect that Encompass Health will post 4.1 EPS for the current year.

Insider Activity at Encompass Health

In related news, CEO Mark J. Tarr sold 44,976 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total value of $3,745,151.52. Following the sale, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Encompass Health news, insider Elissa Joy Charbonneau sold 10,000 shares of Encompass Health stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $85.02, for a total transaction of $850,200.00. Following the transaction, the insider now directly owns 18,594 shares of the company’s stock, valued at $1,580,861.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark J. Tarr sold 44,976 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at $46,139,740.46. The disclosure for this sale can be found here. Insiders have sold 69,519 shares of company stock valued at $5,816,091 over the last three months. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in EHC. Tudor Investment Corp Et Al purchased a new position in shares of Encompass Health during the third quarter worth approximately $2,467,000. Comerica Bank grew its holdings in shares of Encompass Health by 8.3% in the third quarter. Comerica Bank now owns 135,459 shares of the company’s stock worth $9,097,000 after purchasing an additional 10,366 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Encompass Health by 24.4% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 68,052 shares of the company’s stock worth $4,571,000 after purchasing an additional 13,352 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Encompass Health by 0.3% in the third quarter. Vanguard Group Inc. now owns 9,546,953 shares of the company’s stock worth $641,173,000 after purchasing an additional 31,380 shares during the last quarter. Finally, Nordea Investment Management AB grew its holdings in shares of Encompass Health by 21.0% in the fourth quarter. Nordea Investment Management AB now owns 101,705 shares of the company’s stock worth $6,787,000 after purchasing an additional 17,684 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.